Earnings ·
Instil Bio, Inc. reported second quarter 2026 financial results on August 13, 2026
TILInstil Bio, Inc.
Instil Bio, Inc. reported second quarter 2026 financial results on August 13, 2026. The company held $69.9 million in cash and marketable securities as of June 30, 2026, sufficient to fund operations beyond 2027. For the six months ended June 30, 2026, Instil reported a net loss of $8.5 million ($1.25 per share), compared to a net loss of $49.6 million ($7.55 per share) in the prior year period. Research and development expenses decreased significantly to $0.9 million from $12.1 million, while general and administrative expenses fell to $10.5 million from $15.3 million. The company is evaluating potential acquisitions and in-licensing opportunities for novel therapeutic candidates. Instil Bio operates in the biotechnology industry, focusing on identifying and advancing innovative therapeutics.